Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

1. Mok, T.S.
2. Cheng, Y.
3. Zhou, X.
4. Lee, K.H.
5. Nakagawa, K.
6. Niho, S.
7. Chawla, A.
8. Rosell, R.
9. Corral, J.
10. Migliorino, M.R.
11. Pluzanski, A.
12. Noonan, K.
13. Tang, Y.
14. Pastel, M.
15. Wilner, K.D.
16. Wu, Y.-L.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1007/S40265-020-01441-6 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus